Interim findings from the phase 1 DELLphi-300 shows that tarlatamab may induce responses in heavily-pretreated patients with small cell lung cancer.
Tarlatamab (AMG 757), a DLL3-targeted immunotherapy, showed anti-tumor activity with promising response duration in patients with heavily pretreated small cell lung cancer (SCLC), according to interim phase 1 study findings presented during the 2022 World Conference on Lung Cancer.1
The confirmed objective response rate (ORR) observed with tarlatamab treatment in the study was 23%. Out of 106 patients, there were notably 2 complete responses and 22 partial responses. Thirty-seven percent of the study population had target lesion shrinkage of ≥ 30. Stable disease was seen in 31 patients, and progressive disease occurred in 8 patients. The disease control rate was 52%.
The median duration of response was 13.0 months (95% CI, 6.2-14.9 months). Of the patients who responded to treatment with tarlatamab, 11 patients were continuing treatment at the time of data cutoff. The median time to response was 1.8 months (range, 1.2-7.4 months).
“Finding treatments that are effective in metastatic small cell lung cancer has been challenging, just because this is a very, very aggressive disease,” said Hossein Borghaei, DO, MS, chief of Thoracic Medical Oncology and a professor in the Department of Hematology/Oncology at Fox Chase Cancer Center, in a press release.2 “So, this drug, if successful, would address a significant unmet need.”
The open-label, multicenter study of tarlatamab (DELLphi-300, NCT03319940) is primarily evaluating the safety and tolerability of the agent in patients with SCLC and determining its maximum-tolerated dose and recommended phase 2 dose. The secondary end points of the study include pharmacokinetics and preliminary antitumor activity. As exploratory end points, the study is assessing the immunogenicity of tarlatamab and biomarker utility.1
DELLphi-300 included patients with histologically or cytologically confirmed disease that progressed or recurred following at least 1 platinum-based chemotherapy, an ECOG performance status of 0-1, and ≥ 2 measurable lesions. At baseline, the population had a median age of 64 years (32-80 years) and a median of ≥ 3 prior lines of therapy.
In addition to antitumor activity, tarlatamab achieved a median overall survival of 13.2 months (95% CI, 8.8 to not reached. The median progression-free survival was 3.7 months (95% CI, 2.1-5.3 months).
Treatment-related adverse events (TRAEs) of any grade occurred in 92% of patients in the study. Thirty-one percent of the TRAEs observed in the study were grade ≥ 3. The most common any-grade TRAEs included cytokine release syndrome (CRS; 53%), pyrexia (38%), dysgeusia (23%), fatigue (22%), and nausea (20%). Come grade ≥ 3 events including fatigue (3%), pyrexia (2%), and CRS (1%).
Four percent of patients in the study discontinued treatment with tarlatamab because of TRAEs including pneumonitis (n = 2), encephalopathy (n =1), neurotoxicity (n = 1), and pneumonitis (n = 2).
TRAES of interest included CRS, neurologic events, and neutropenia. Cases of CRS were largely grade 1 and rarely recurred. There were no events of grade 4 or 5 CRS during the study. Neurologic events were also predominantly low grade, but 5 patients experienced grade ≥ 3 confusion. Grade 4 neutropenia occurred in 4 patients. There were no febrile neutropenia events.
Across all dose levels assessed, tarlatamab displayed a manageable safety profile.
Based on the positive phase 1 results, a phase 3 registrational study of tarlatamab (DELLphi-201; NCT05060016) has been initiated in patients with SCLC who have received ≥ 2 prior lines of therapy.
REFERENCES:
1. Borghaei H, Paz-Ares L, Johnson M, et al. Phase 1 updated exploration and first expansion data for DLL3-targeted t-cell engager tarlatamab in small cell lung cancer. Presented at: International Association for the Study of Lung Cancer 2022 World Conference on Lung Cancer; August 6-9, 2022; Vienna, Austria. Abstract OA12.05
2. Tarlatamab shows efficacy against metastatic small cell lung cancer in phase 1 study. News release. Fox Chase Cancer Center. August 8, 2022. Accessed August 10, 2022. https://bit.ly/3Qh7JaY
Carrizosa Explores Trials of Immunotherapy in Extensive-Stage Small Cell Lung Cancer
May 24th 2024In an in-person Community Case Forum event in partnership with the North Carolina Oncology Association and South Carolina Oncology Society, Daniel Carrizosa, MD, MS, discussed the use of the immunotherapies durvalumab and atezolizumab in patients with small cell lung cancer.
Read More